Xiaolin Wang - 01 Mar 2026 Form 4 Insider Report for Revolution Medicines, Inc. (RVMD)

Reporting relationship: EVP, Clinical Development
Issuer ticker: RVMD
Reported as of: 01 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Mar 2026, 21:11:14 UTC
Prior SEC filing: 19 Mar 2025
Next SEC filing: 19 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Jack Anders, as Attorney-in-fact for Xiaolin Wang

Key filing fact

Xiaolin Wang filed Form 4 for Revolution Medicines, Inc. (RVMD) on 03 Mar 2026.

Key facts

This page summarizes Xiaolin Wang's Form 4 filing for Revolution Medicines, Inc. (RVMD).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 03 Mar 2026, 21:11.

Change

Previous filing in this sequence was filed on 19 Mar 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001849181 Primary reporting owner

Wang Xiaolin

Relationship: EVP, Clinical Development
Address: C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY
Signature: /s/ Jack Anders, as Attorney-in-fact for Xiaolin Wang
Signature date: 03 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RVMD transaction

Common Stock

Award

Transaction value: $0
Shares: +15,100
Change %: +15%
Price: $0.000000
Shares after: 118,073
Date: 01 Mar 2026
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RVMD transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +34,000
Change %
Price: $0.000000
Shares after: 34,000
Date: 01 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 34,000
Exercise price: $102.02
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Includes 54,464 restricted stock units.

Footnote F2

Includes 652 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2025.

Footnote F3

One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2026 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

SEC remarks

EVP, Clinical Development